IRIDEX Announces MicroPulse Transscleral Laser Therapy Now Accepted in the European Glaucoma Society Guidelines
December 22 2020 - 4:05PM
IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative
ophthalmic laser-based medical products for the treatment of
glaucoma and retinal diseases, reports that MicroPulse Transscleral
Laser Therapy (TLT), which is performed using the IRIDEX Cyclo G6®
Laser System and MicroPulse P3® Delivery Device, has been included
in the European Glaucoma Society (EGS) Terminology and Guidelines
for Glaucoma. The EGS guidelines represent recommendations on the
diagnosis and management of glaucoma to standardize practice within
the European Union. The new guidelines, the Society’s 5th edition,
were presented at the Annual EGS Meeting on December 12-13, 2020.
“We are very encouraged with the broadening
recognition of MicroPulse TLT in the ophthalmic community,” said
David Bruce, CEO, IRIDEX. “Inclusion in the EGS guidelines plus
nine papers presented in the Society’s meeting shows the growing
adoption of this effective non-incisional therapy for the
management of glaucoma disease.”
MicroPulse TLT is a non-incisional procedure
that substantially reduces intraocular pressure (IOP) for a broad
range of glaucoma types and severity. The procedure can be used for
primary open-angle, closed-angle, and refractory glaucoma. It’s a
repeatable treatment option that can be performed before, during,
or after other glaucoma interventions. More than 140,000 patients
have been treated with MicroPulse TLT in top ophthalmic hospitals
around the globe.
Also presented at the EGS meeting, were nine
MicroPulse TLT studies. These studies were conducted in several
countries which exemplify the continued global expansion of
MicroPulse TLT. Featured studies included:
- P248: MicroPulse
Transscleral Cyclophotocoagulation: Step by Step; Rita
Basto, et al. (Poland) This study represents a 6-month
retrospective review of glaucoma patients (38 eyes) treated with
MicroPulse TLT. The percentage of IOP reduction was 43.4 ± 16.2%
(8.9% - 70.6%). A success rate (defined as >20% IOP reduction
and IOP ≤ 21 mmHg) was obtained in 81.6% of cases with no records
of serious complications. The authors concluded that MicroPulse TLT
is easily performed, can be repeated with good results, is an
efficient and safe strategy to reduce IOP, and can be used in a
wide spectrum of glaucoma disease.
- P350: Use
of MicroPulse Transscleral
Cyclophotocoagulation in Glaucoma Associated with Penetrating
Keratoplasty or KPRO; Consuelo Gajardo Menzel, et al.
(Peru) The authors presented 1-year follow-up of MicroPulse TLT in
glaucomatous patients with corneal grafts. Patients’ IOP was
reduced by an average of 50%, and the authors concluded that
MicroPulse TLT in patients with corneal transplants is effective
and safe.
- P359:
Microimpulse Cyclophotocoagulation in
Combined Neovascular Glaucoma Treatment; Nazir Khodzhaev,
et al. (Russia) This study evaluated a combined treatment of
anti-vascular endothelial growth factors (VEGF) injections and
MicroPulse TLT in 15 patients (15 eyes) with secondary neovascular
glaucoma (NVG). Initial outcomes demonstrated an IOP reduction of
approximately 26%, with a reduction in drops from 3.5 to 2.7,
concluding that anti-VEGF and MicroPulse TLT are a safe and
effective treatment in NVG patients.
- 430: Topical Anesthesia for
Diode Transscleral MicroPulse
Cyclophototherapy; Maria Cecilia
Aquino, et al. (Singapore)This study evaluated the use of topical
anesthesia and oral paracetamol in a prospective case series of 22
patients receiving MicroPulse TLT. Although a majority of patients
experienced moderate pain during treatment, all patients tolerated
the entire treatment lasting for 100 seconds without additional
peribulbar anesthesia. The post-operative pain in the immediate
24-hours after treatment was unremarkable requiring no oral
analgesic medications.
Other studies presented:
- P043: MicroPulse Transscleral Laser in Children - The Auckland
and Singapore Experience; Marcus Tan, et al. (New Zealand)
- P211: Short-term Efficacy and Safety of MicroPulse Transscleral
Cyclophotocoagulation in Asian Glaucoma Patients; Mi Sun Sung, et
al. (South Korea)
- P226: Mid-Term Results of Micro-Pulse Transscleral
Cyclophotocoagulation with Diode Laser on Treatment of Glaucoma: A
Retrospective Analysis; Guido Barosco et al. (Italy)
- P245: Outcomes of MicroPulse transscleral cyclophotocoagulation
in Patients with Glaucoma – A Case Series; Wojciech Maruszczyk, et
al. (Poland)
- P485: A Modified MicroPulse Transscleral Cyclophototherapy
technique for the Treatment of Refractory Glaucoma; Victor Teck
Koh, et al. (Singapore)
More information can be found at: www.iridex.com/egs
About IRIDEXIRIDEX is a
worldwide leader in developing innovative and versatile laser-based
medical systems, delivery devices and consumable instrumentation
for the ophthalmology market. The Company’s proprietary MicroPulse®
technology delivers a differentiated treatment that provides safe,
effective, and proven treatment for targeted sight-threatening eye
conditions. IRIDEX’s current product line is used for the
treatment of glaucoma, diabetic macular edema and other retinal
diseases. IRIDEX products are sold in the United States and
Germany through a direct sales force and in more than 100 countries
through a network of independent distributors. For more
information, visit www.iridex.com/MicroPulseP3.
Investor Relations ContactLeigh Salvo(415)
937-5404investors@iridex.com
Media ContactJamie Hall Pascale Communications, LLC.(724)
417-0167jamie@pascalecommunications.com
IRIDEX (NASDAQ:IRIX)
Historical Stock Chart
From May 2024 to Jun 2024
IRIDEX (NASDAQ:IRIX)
Historical Stock Chart
From Jun 2023 to Jun 2024